Wednesday, February 10, 2010, 8:46am EST - Canadian Markets open in 44 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

OSI Pharmaceuticals Inc. (OSIP)

 On Feb 9: 34.18 USD   0.00 (0.00%)  
MORE ON OSIP
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
OSI Pharmaceuticals Inc. (NasdaqNM:OSIP) Delayed quote dataEdit
Last Trade: 34.18 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 34.18
Open: N/A
Bid: 32.27 x 100
Ask: 36.00 x 100
1y Target Est: 38.60
Day's Range: N/A - N/A
52wk Range: 27.01 - 42.44
Volume: 0
Avg Vol (3m): 871,535
Market Cap: 1.98B
P/E (ttm): 5.27
EPS (ttm): 6.49
Div & Yield: N/A (N/A%)
OSI Pharmaceuticals Inc. (OSIP)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add OSIP to Portfolio   Download Data

HEADLINES
• [$$] Rob's Wrap: OSIP, FXP, VSH, SLE
at RealMoney by TheStreet.com (Tue 4:45pm)
• OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2009 Financial Results on February 23, 2010
Business Wire (Tue 10:36am)
• Novella Clinical and OSI Pharmaceuticals Expand Clinical Services Agreement
Business Wire (Thu, Jan 28)
• 67% Decline In Consumable Cost For Human Genome Sequencing Seen In 2010 By First Analysis Equity Valuation Expert
Wall Street Transcript (Wed, Jan 27)
• Pfizer's Great Data Won't Do Much
at Motley Fool (Fri, Jan 22)
• Today's 5-Star Movers
at Motley Fool (Wed, Jan 20)
• OSI PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 19)
• FDA Extends Tarceva Review
Zacks.com (Mon, Jan 18)
• UPDATE - OSI Pharma says FDA extends Tarceva review
at Reuters (Fri, Jan 15)
• FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Business Wire (Fri, Jan 15)
• OSI reports 17 percent boost in Tarceva sales
AP (Tue, Jan 12)
More Headlines for OSIP...
ANALYST
EPS Est (next year) (Dec-09) : 1.29
EPS Est (in 2 years) (Dec-10) : 1.61
Avg Rec (current)*: 2.4
PEG Ratio: 1.93
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices